Clinical trials: Tetanus
Respiratory Tract Infection
A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS
This phase 2b study will evaluate safety, tolerability, and immunogenicity of an RSV vaccine when given together with Tdap in approximately 710 healthy nonpregnant women 18 through 49 years of age.
- Trial name
- NCT04071158
- Testing
- RSV Vaccine, Tdap
- Where
- 16 sites in United States
- Volunteers
- 713 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diphtheria, Tetanus
Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine
This study was designed to assess the lot comparability of DAPTACEL, as well as the safety and immunogenicity of DAPTACEL when co-administered with other recommended infant vaccines. Stage I Primary Objectives: 1.
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Polio
- Trial name
- NCT00662870
- Testing
- DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine), Pentacel: DTaP-IPV/Hib
- Where
- 26 sites in United States
- Volunteers
- 1,941 people, healthy volunteers welcome
- Sponsor
- Sanofi
Infections, Meningococcal
Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects
The purpose of this study is to assess the safety and reactogenicity of a booster dose of diphtheria-tetanus-whole cell pertussis-hepatitis B virus/Haemophilus influenzae type b vaccine (DTPw-HBV/Hib) at 15-18 m and to assess the…
- Trial name
- NCT00317109
- Testing
- Tritanrix™- HepB, Hiberix™, Mencevax™ ACW
- Where
- 3 sites in South Africa
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pertussis, Diphtheria
Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants
Pediacel™ is currently licensed in the UK for use as a 3 dose regimen for the active immunisation of infants against Diphtheria, Tetanus, Pertussis, Poliomyelitis and invasive infections caused by Haemophilus influenzae type b.
- Conditions
- Pertussis, Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT00287092
- Testing
- DT5aP-IPV-Hib 5-component Pertussis vaccine, Infanrix® -IPV+Hib
- Where
- 14 sites in Finland, Sweden
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis A
Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months
This is a study to evaluate the immune response and safety of GSK Biologicals 2-dose inactivated hepatitis A vaccine when administered with a diphtheria, tetanus and pertussis combination (DTaP) vaccine and a Haemophilus…
- Trial name
- NCT00197236
- Testing
- Havrix™, Infanrix™, ActHIB™
- Where
- 22 sites in United States
- Volunteers
- 468 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus
Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.
To demonstrate that DTaP-IPV-HB-PRP~T combined vaccine does not induce a higher incidence rate of high fever than Tritanrix-HepB/Hib™ and Oral Polio Vaccine (OPV) after any of the three vaccinations at 2, 4, and 6 months of age…
- Conditions
- Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT00313911
- Testing
- DTaP-IPV-HB-PRP~T, Tritanrix-HepB/Hib
- Where
- 2 sites in Mexico, Peru
- Volunteers
- 2,133 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria-Tetanus-acellular Pertussis Vaccines
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women
The purpose of this study is to assess the immunogenicity and safety of Boostrix™ when compared to a placebo given during 27-36 weeks of gestation in healthy women aged 18-45 years.
- Trial name
- NCT02377349
- Testing
- Boostrix™
- Where
- 35 sites in Australia, Canada and 4 more
- Volunteers
- 688 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus
Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents
This study is designed to assess the immunogenicity and safety of DTaP vaccine (BK1301) as a booster dose in adolescents. The purposes of this study are as follows: To confirm the non-inferiority of BK1301 to Adsorbed…
- Conditions
- Diphtheria, Tetanus, Pertussis
- Trial name
- NCT02118961
- Testing
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301), Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)
- Where
- 7 sites in Japan
- Volunteers
- 446 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Diphtheria-Tetanus-acellular Pertussis Vaccines
Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects
Diphtheria, tetanus and pertussis are common causes of diseases worldwide, with significant morbidity and mortality. The purpose of this study is to assess the immunogenicity, safety and reactogenicity of a single dose of…
- Trial name
- NCT03311659
- Testing
- Boostrix
- Where
- 8 sites in Russia
- Volunteers
- 448 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus
Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®
Primary Objectives: 1. To present the safety profile after a 5th dose of DAPTACEL® in children 4 to 6 years of age who have previously received 4 doses of DAPTACEL® or Pentacel™. 2.
- Conditions
- Diphtheria, Tetanus, Pertussis
- Trial name
- NCT00258895
- Testing
- DAPTACEL®: DTaP
- Where
- 22 sites in United States
- Volunteers
- 649 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Tetanus
A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection
The goal of this clinical trial is to compare the efficacy and safety of GR2001 injection with Human Tetanus Immunoglobulin(HTIG) in tetanus prophylaxis. Patients will receive either GR2001 injection or HTIG on study D0.
- Trial name
- NCT06635798
- Testing
- GR2001, HTIG
- Where
- 20 sites in China
- Volunteers
- 582 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Diphtheria, Tetanus
Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents
The purpose of the study is to compare the immunogenicity and safety of a booster dose of BoostrixTM administered in a new syringe presentation to that of BoostrixTM administered in the previous syringe presentation in healthy…
- Conditions
- Diphtheria, Tetanus, Acellular Pertussis
- Trial name
- NCT01362322
- Testing
- Boostrix TM (new syringe presentation), Boostrix TM (previous syringe presentation)
- Where
- 3 sites in Chile, Mexico
- Volunteers
- 671 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tetanus
Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus
TNM002 Injection is a recombinant fully human native monoclonal antibody (mAb) against tetanus toxin and is currently under development for indication of prophylaxis against tetanus.
- Trial name
- NCT05664750
- Testing
- TNM002, Human tetanus immunoglobulin (HTIG)
- Where
- 28 sites in China
- Volunteers
- 675 people
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
Diphtheria, Pertussis
Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults
The aim of the study is to assess the safety and immunogenicity of GlaxoSmithKline Biologicals' (formerly known as SmithKline Beecham Biologicals) combined diphtheria-tetanus-acellular pertussis vaccine in healthy adults, from…
- Conditions
- Diphtheria, Pertussis, Tetanus
- Trial name
- NCT01267058
- Testing
- GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine, GSK Biologicals' acellular pertussis vaccine, Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus and Acellular Pertussis
A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)
The combined pertussis, diphtheria and tetanus vaccine, the first vaccine to be included in the Expanded Programme of Immunization(EPI) of World Health Organization(WHO), has played an important role in the prevention and control…
- Trial name
- NCT05951725
- Testing
- Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP), Diphtheria，Tetanus and Acellular Pertussis Combined Vaccine，DTaP, Diphtheria,tetanus,pertussis(acellular,component),Inactivated polio vaccine(adsorbed）and Haemophilus influenzae type b conjugate vaccine,adsorbed,DTaP-IPV-Hib
- Where
- China
- Volunteers
- 2,520 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Tetanus, Poliomyelitis
Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)
This study is designed to evaluate the safety and immunogenicity of new formulations of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine (GSK217744) when administered as a primary vaccination course to healthy infants at 2, 3 and 4…
- Conditions
- Tetanus, Poliomyelitis, Hepatitis B, Haemophilus Influenzae Type b
- Trial name
- NCT01248884
- Testing
- Infanrix hexa™, Prevenar 13®, GSK217744
- Where
- 16 sites in Dominican Republic, Finland
- Volunteers
- 721 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tetanus
A Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
Study sites were selected from hospitals across diverse regions of China. Approximately 6,000 participants who require passive immunization against tetanus due to various injuries (including those with severe wounds or heavily…
- Trial name
- NCT07347938
- Testing
- Siltartoxatug Injection, HTIG/TAT/F(ab')₂
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
Diphtheria, Tetanus
DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants
The aim of this study is to evaluate the immunogenicity and safety of a novel DTaP-IPV-Hep B-PRP~T fully liquid combined hexavalent vaccine (study vaccine) administered at 2, 4, and 6 months of age compared to Sanofi Pasteur's…
- Conditions
- Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b Infection
- Trial name
- NCT02094833
- Testing
- DTaP-IPV-Hep B-PRP~T combined vaccine, DTaP-IPV//PRP~T and Hepatitis B vaccine
- Where
- 16 sites in South Korea
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Acellular Pertussis
Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants
The purpose of this study is to assess the immunogenicity and safety of DTPa-IPV/Hib when administered at 6, 10 and 14 weeks to healthy Indian infants, as per guidance from the Indian regulatory authority.
- Conditions
- Diphtheria, Acellular Pertussis, Haemophilus Influenzae Type b, Tetanus
- Trial name
- NCT03128489
- Testing
- Infanrix-IPV/Hib
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Poliomyelitis, Tetanus
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).
This study will evaluate the immunogenicity of the co-administration of different combinations of DTPa, IPV, hepatitis B, Hib and Men C vaccines during the first year of life.
- Conditions
- Poliomyelitis, Tetanus, Acellular Pertussis, Hepatitis B
- Trial name
- NCT00352963
- Testing
- Study vaccines: IH+Hib-MenC/NVC; Control: IH+Meningitec
- Where
- 22 sites in Spain
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline